# Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS

> **NCT04374149** · PHASE2 · COMPLETED · sponsor: **Prisma Health-Upstate** · enrollment: 20 (actual)

## Conditions studied

- Cytokine Release Syndrome
- COVID19

## Interventions

- **PROCEDURE:** Therapeutic Plasma Exchange
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04374149
- **Lead sponsor:** Prisma Health-Upstate
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-30
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-12-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04374149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04374149, "Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04374149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*